Risk of contamination of semen, vaginal secretions, follicular fluid and ovarian medulla with SARS-CoV-2 in patients undergoing ART.

STUDY QUESTION: Can severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA be detected in the reproductive tract of asymptomatic patients undergoing ART? SUMMARY ANSWER: SARS-CoV-2 mRNA is not detectable in semen, follicular fluid, vaginal secretions or residual medulla from ovarian tissue cryopreservation procedures in asymptomatic patients who undergo ART, irrespective of the results of a triage questionnaire and a nasopharyngeal SARS-CoV-2 RNA detection test. WHAT IS KNOWN ALREADY: The SARS-CoV-2 pandemic had a huge impact on the activities of fertility clinics. Although some studies reported the presence of SARS-CoV-2 mRNA in the reproductive system during or after acute COVID-19 symptomatic infections, uncertainties remain regarding the presence of viral mRNA in the reproductive material and follicular fluid of asymptomatic patients undergoing ART. STUDY DESIGN, SIZE, DURATION: An observational cohort trial of residual material samples including semen, follicular fluid, vaginal secretions and ovarian medulla was conducted during the second pandemic wave in Brussels from September 2020 to April 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: All patients who underwent ART (IUI, IVF/ICSI, oocyte and ovarian tissue cryopreservation) responded to a triage questionnaire at the beginning and end of the cycle and underwent nasopharyngeal swab collection for SARS-CoV-2 RNA detection by RT-PCR before the procedure according to standard recommendations. For semen analysis, only the questionnaire was requested the day before the sample collection. The ART cycles of patients with positive nasopharyngeal SARS-CoV-2 RNA detection tests and/or questionnaires were cancelled except for those that could not be postponed. After providing informed consent, swabs on residual materials were collected the day of the oocyte, ovarian tissue or semen collection and were processed for RT-qPCR. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 394 samples from 291 patients were analysed. Amongst them, 20 samples were obtained from patients with a positive questionnaire but negative nasopharyngeal SARS-CoV-2 test and 20 others were from patients with a positive nasopharyngeal SARS-CoV-2 test. The remaining samples were collected from patients with a negative or unknown nasopharyngeal SARS-CoV-2 test and/or a negative or unknown triage questionnaire. Viral RNA for SARS-CoV-2 was undetectable in all of the samples. LIMITATIONS, REASONS FOR CAUTION: Considering the cancellation policy, only a limited number of samples from patients with positive triage questionnaires or nasopharyngeal SARS-CoV-2 tests were included in the analysis. WIDER IMPLICATIONS OF THE FINDINGS: The study suggested that there was no risk of reproductive tract contamination by SARS-CoV-2 in asymptomatic patients, irrespective of the results from a triage questionnaire or nasopharyngeal SARS-CoV-2 test. The results suggested that no additional measures to prevent staff or cross-patient contamination need to be implemented in the IVF and andrology laboratories. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Université Libre de Bruxelles and by a grant from Ferring. A.D. and I.D. received a grant from Ferring for the study. The authors have no other conflict of interest to declare related to this study. TRIAL REGISTRATION NUMBER: N/A.

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.

Background: Preclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical data are available. This study assessed the reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Patients and methods: This was a retrospective analysis of two prospective studies investigating oocyte cryopreservation and ovarian tissue cryopreservation in newly diagnosed early breast cancer patients. In the current analysis, baseline anti-Mullerian hormone (AMH) and performance of cryopreservation strategies were compared between patients with or without germline deleterious BRCA mutations. Results: Out of 156 patients included, 101 had known BRCA status of whom 29 (18.6%) were BRCA-mutated and 72 (46.1%) had no mutation. Median age in the entire cohort was 31 years [interquartile range (IQR) 28-33). Median AMH levels were 1.8 µg/l (IQR 1.0-2.7) and 2.6 µg/l (IQR 1.5-4.1) in the BRCA-positive and BRCA-negative cohorts, respectively (P = 0.109). Among patients who underwent oocyte cryopreservation (N = 29), women in the BRCA-positive cohort tended to retrieve (6.5 versus 9; P = 0.145) and to cryopreserve (3.5 versus 6; P = 0.121) less oocytes than those in the BRCA-negative cohort. Poor response rate (i.e. retrieval of ≤4 oocytes) was 40.0% and 11.1% in the BRCA-positive and BRCA-negative cohorts, respectively (P = 0.147). Among patients who underwent ovarian tissue cryopreservation (N = 72), women in the BRCA-positive cohort tended to have a numerically lower number of oocytes per fragment (0.08 versus 0.14; P = 0.193) and per square millimeter (0.33 versus 0.78; P = 0.153) than those in the BRCA-negative cohort. Two BRCA-mutated patients were transplanted after chemotherapy and one delivered at term a healthy baby. No difference between BRCA1- and BRCA2-mutated patients was observed in any of the above-mentioned outcomes. Conclusion: A consistent trend for reduced reproductive potential and performance of cryopreservation strategies was observed in BRCA-mutated breast cancer patients. Independent validation of these results is needed.

Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis.

STUDY QUESTION: Do the benefits of ovarian tissue cryopreservation outweigh the risks for patients seeking to preserve fertility before gonadotoxic treatment in various indications? SUMMARY ANSWER: In >90% of the patients undergoing cryopreservation of ovarian tissue, oncological treatment was associated with a reduced ovarian reserve and in 30% of patients, premature ovarian failure (POF) occurred within 5 years. WHAT IS KNOWN ALREADY: Ovarian tissue cryopreservation is an effective fertility preservation option, especially for pre-pubertal patients and patients who have a short time between diagnosis of a disease and gonadotoxic treatment. STUDY DESIGN, SETTING, DURATION: This study retrospectively analysed ovarian function and fertility recovery rates, as well as ovarian tissue characteristics, of patients who underwent ovarian tissue cryopreservation at Erasme Hospital between 1999 and 2011. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: A total of 225 patients referred from 15 Belgian oncological units underwent cryopreservation of ovarian tissue before gonadotoxic therapy for malignant or benign diseases. There were 28 patients (12.4%) who died during follow-up due to recurrence of disease. One severe adverse event occurred during anaesthesia for ovarian tissue collection, leading to the death of the patient. Ovarian function and fertility outcomes were available for 114 patients including 13 girls who were pre-pubertal at the time of the procedure. Eight patients had undergone ovarian tissue transplantation in order to restore their fertility after remission of the disease. MAIN RESULTS AND THE ROLE OF CHANCE: Breast cancer and haematological disease were the most frequent indications for ovarian tissue cryopreservation. Overall, 90% of post-pubertal patients were diagnosed with poor ovarian reserve (AMH < 0.5 ng/ml) after a mean of 50 months of follow-up (11-125 months), including 30% with POF (FSH > 40 IU/ml). Breast cancer patients had a lower rate of POF than did post-pubertal patients with haematological diseases (11 versus 34.5%, respectively), despite the older age (mean 31 versus 23.5 years old, respectively) of the breast cancer patients. Ovarian function returned in 71 post-pubertal patients without the need for grafts of cryopreserved tissue. Spontaneous pregnancies were reported for 33 of them, leading to 34 live births. Among the 13 pre-pubertal patients who reached pubertal age during the follow-up, 10 had POF. Eight patients received cryopreserved ovarian grafts to reverse POF and three of them have already become pregnant. LIMITATIONS, REASONS FOR CAUTION: This study is a retrospective analysis. The cohort was not compared with a control group of patients who did not undergo the procedure. WIDER IMPLICATIONS OF THE FINDINGS: After careful evaluation of the surgical risks, ovarian tissue cryopreservation can be proposed as an efficient option to preserve the fertility of children and young adults facing gonadotoxic therapies. However, alternative procedures such as oocyte or embryo cryopreservation should be considered as first options especially for older patients or if there is high risk of neoplastic cells within the ovaries. STUDY FUNDING/COMPETING INTEREST: This study was supported by the Télévie, FNRS-FRSM and Fondation Belge contre le cancer. There are no competing interests to report.

Inspector General wins round two of Hanlester Case.

The decision of the HHS Departmental Appeals Board Appellate Division in Inspector General v. Hanlester Network provides guidance as to the aspects of joint ventures that pose fraud and abuse concerns by listing the factors that may indicate an improper purpose. Together with the fraud and abuse safe harbors, the decision helps identify the pitfalls associated with physician investment in suspect joint ventures. This article analyzes the latest Hanlester decision, forecasts the future of joint venturing after Hanlester and the safe harbors, and offers some guidance to potential investors in light of these developments.

Physician and provider obligations under the Medicare antidumping provisions.

The Medicare antidumping provision enacted in 1986 and revised in 1989 has serious implications, not only for hospitals, but also for physicians who provide care for emergency patients. In this article, the author discusses the obligations of health care providers under that provision, some recent developments under the emerging case law, and the implications of these developments for physicians.

Physician and provider obligations under the Medicare antidumping provision.

The Medicare antidumping provision enacted in 1986 and revised in 1989 has serious implications, not only for hospitals, but also for physicians who provide care for emergency patients. In this article, the author discusses the obligations of health care providers under that provision, some recent developments under the emerging case law, and the implications of these developments for physicians.

Anaesthesia for ambulatory surgery.

Most surgeons and hospital administrators now recognize that many surgical procedures can be done on an out-patient basis and anesthetists have been instrumental in developing and implementing the practice of short-stay surgery. It is our opinion that general anaesthesia using enflurane and Alfathesin will increase the safety of ambulatory surgery.

Alfentanil as an adjunct to thiopentone and nitrous oxide in short surgical procedures.

Alfentanil, a new narcotic analgesic with a rapid onset and short duration of action was used as an adjunct to thiopentone and nitrous oxide anaesthesia in 109 patients undergoing dilatation and curettage (D&C) or therapeutic abortion (TA). The mean alfentanil dose was 19.7 +/- 9.6 microgram X kg-1 (D&C Group) and 23.3 +/- 6.6 micrograms X kg-1 (TA Group), with a mean duration of anaesthesia of about 30 minutes. The anaesthetic effect was judged excellent in virtually all patients (94.7 per cent in the TA group and 96.7 per cent in the D&C group). There were no significant changes in haemodynamic parameters intraoperatively. Apnea or hypoventilation was observed in four patients and was easily reversed by naloxone. Most patients (95.4 per cent) demonstrated complete recovery of consciousness, motor activity, respiratory and circulatory function and skin colour within 60 minutes of arrival in recovery room. The only consistent side effect was minor chest wall rigidity which was eliminated by pretreatment with d-tubocurarine. One patient experienced a serious adverse reaction which was reversed with naloxone. We have found alfentanil to be well suited as an adjunct to nitrous oxide and thiopentone in short surgical procedures.

Alphathesin, a new steroid anaesthetic agent.

This is a study of 220 patients, most of them out-patients, who were anaesthetized with Alphatehsin. Although the use of Alphathesin has not been discussed in depth, one can say that it is not a substitute for other intravenous anaesthetics available at the present time. Alphathesin, however, deserves further study as it may be able to supply new solutions to new problems which are encountered daily in our specialty, particularly in the field of out-patient surgery.

What the regulatory developments mean for pathologist-hospital contracts.

Flexibility is a key concern today for pathologists negotiating contracts with hospitals. Here, the authors explain why it is important, and they pinpoint specific contractual provisions that provide this flexibility.

CAP v. Heckler and HCFA's modification of TEFRA regulations.

Although the Court of Appeals did not invalidate the Health Care Financing Administration's TEFRA regulations, HCFA did make favorable changes in the regulations in response to the College's lawsuit. Here, the authors detail the important areas in which HCFA reversed its position during the course of the litigation, and describe other aspects of the suit.

The prognosis for the hospital-based pathologist--Part 2.

Last month the authors diagnosed the condition of the hospital-based pathologist and prescribed a large dose of competitive activities to improve security and financial well-being. In this concluding article the complications of this treatment are examined, highlighting the issues that pathologists must resolve as they venture forth into a new practice environment.

[Isotopic scintigraphy in the diagnosis of the spread of bronchial cancer]. / A propos de la scintigraphie isotopique dans les diagnostics d'extension des cancers bronchiques.

Ventilation of the lungs using Xenon 133 and perfusion scans using 99m Tc albumin particles in microspheres were performed on 455 patients with bronchial cancers and 55 patients with pulmonary metastases. Ventilation-perfusion mismatch and functional defects of the lung, which are never found in nodular-shaped pulmonary metastases, vary in frequency according to the anatomo-pathological type of the tumor and constitute a limiting factor for ablation.